Development and acceptability of a decision‐aid for food allergy oral immunotherapy in children
This first pediatric OIT decision-aid, agnostic to product, allergen, and age has good acceptability, limited bias, and is associated with low decisional conflict and high decisional self-efficacy. It supports SDM in navigating the decision to start OIT or continue allergen avoidance.
Authors
- Edmond S. Chan (ORCID: https://orcid.org/0000-0003-2947-1175)
- Aikaterini Anagnostou (ORCID: https://orcid.org/0000-0001-6240-7437)
- Hannah Jaffee
- Matthew Greenhawt (ORCID: https://orcid.org/0000-0002-2365-9372)
- Julie Wang (ORCID: https://orcid.org/0000-0001-5956-0123)
- Melanie Carver
- Justin Greiwe (ORCID: https://orcid.org/0000-0001-6143-2323)
- Phil Lieberman (ORCID: https://orcid.org/0000-0002-6917-4100)
- Elissa M. Abrams (ORCID: https://orcid.org/0000-0003-3433-1986)
- S. Shahzad Mustafa (ORCID: https://orcid.org/0000-0001-9691-7590)
- Douglas P. Mack (ORCID: https://orcid.org/0000-0002-9800-0951)
- Sanaz Eftekhari (ORCID: https://orcid.org/0000-0002-4419-4973)
- Marcus Shaker
- David R. Stukus
Institutions
- Dartmouth College (US)
- Dartmouth–Hitchcock Medical Center (US)
- Nationwide Children's Hospital (US)
- University of British Columbia (CA)
- University of Tennessee Health Science Center (US)
- Asthma and Allergy Foundation of America (US)
- Children's Hospital Colorado (US)
- Unity Health System (US)
- Bernstein Clinical Research Center (US)
- Texas Children's Hospital (US)
- BC Children's Hospital (CA)
- University of Manitoba (CA)
- University of Rochester (US)
- University of Cincinnati Medical Center (US)
- University of Colorado Denver (US)
- McMaster University (CA)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Allergy
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1111/all.16332
- Citations
- 9
- Primary Topic
- Patient-Provider Communication in Healthcare
- Type
- article
- Field-Weighted Citation Impact
- 7.64
Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- CSL Behring
- Regeneron Pharmaceuticals
- Public Health Agency of Canada
- Celldex Therapeutics
- Asthma and Allergy Foundation of America
- Aimmune Therapeutics
- Incyte
- Public Health Agency
- Bausch Health
- LEO Pharma
- National Institutes of Health
- Genentech
- Sanofi Genzyme